98%
921
2 minutes
20
The global burden of ischemic stroke requires a search for new factors that affect its risk and outcomes. Recent studies have shown that triiodothyronine could potentiate favorable stroke outcomes, but the reason for this is still unclear. To clarify the effects of the free triiodothyronine (fT3) level on stroke outcomes, we adopted a Mendelian randomization (MR) approach to evaluate their causal relationship. The genetic variants associated with the free triiodothyronine (fT3) level were obtained from the ThyroidOmics Consortium. Thirteen single-nucleotide polymorphisms, genetically predicting the fT3 level with a significance of < 10, were adopted for MR analysis. Summary-level data for ischemic stroke outcomes (reported as a continuous variable, namely the modified Rankin score 3 months after stroke) was obtained from the GISCOME network. MR analyses were performed using the TwoSampleMR framework. The inverse-variance weighting method of MR analysis showed that a genetically predicted increase in fT3 level is associated with a reduction in ordinal Modified Rankin Scale scores (OR = 0.581, 95% CI 0.37-0.92, = 0.0183). This study showed that higher fT3 levels could be causally associated with more favorable ischemic stroke outcomes and provides more evidence for the possibility of using thyroid hormone (TH) analogs to improve stroke outcomes.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12387972 | PMC |
http://dx.doi.org/10.3390/life15081303 | DOI Listing |
Stroke
September 2025
Departments of Radiology and Neurology, Neuroprotection Research Laboratories, Massachusetts General Hospital, Harvard Medical School, Boston (E.L., R.M.P., K.H., E.H.L., E.E.).
Background: Despite promising preclinical results, remote limb ischemic postconditioning efficacy in human stroke treatment remains unclear, with mixed clinical trial outcomes. A potential reason for translational difficulties could be differences in circadian rhythms between nocturnal rodent models and diurnal humans.
Methods: Male C57BL/6J mice were subjected to transient focal cerebral ischemia and then exposed to remote postconditioning during their active or inactive phase and euthanized at 24 hours and 3 days.
Arterioscler Thromb Vasc Biol
September 2025
Institute of Cardiovascular Diseases and Department of Cardiology, Ultrasound in Cardiac Electrophysiology and Biomechanics Key Laboratory of Sichuan Province, Sichuan Provincial People's Hospital, School of Medicine, University of Electronic Science and Technology of China, Chengdu (K.L., H.M., W.J
Background: The estimated glucose disposal rate (eGDR) is a validated surrogate marker of insulin resistance. However, its association with stroke and dementia in nondiabetic populations remains insufficiently investigated.
Methods: This prospective cohort study included nondiabetic participants from the UK Biobank.
Stroke
September 2025
Department of Neurology, Vagelos College of Physicians and Surgeons, Columbia University, New York. (F.C.P., M.R., M.S., A.K., S.G., S.A., S.P., J.C., D.J.R.).
Background: Major ABO-incompatible platelet transfusions are associated with poor intracerebral hemorrhage (ICH) outcomes, yet drivers for this relationship remain unclear. Brain magnetic resonance imaging (MRI) ischemic lesions after ICH are neuroimaging biomarkers of secondary brain injury and are associated with poor outcomes. Given that ABO-incompatible platelet transfusions can induce immune complex formation, thrombo-inflammation, and endothelial barrier disruption, factors that could exacerbate cerebral ischemia, we explored whether major ABO-incompatible platelet transfusions are risk factors for ischemic lesions on brain MRI after ICH.
View Article and Find Full Text PDFCirc Genom Precis Med
September 2025
Division of Cardiology, Emory University School of Medicine, Atlanta, GA. (A.K.Y., A.C.R., L.S.S., A.A.Q., Y.V.S.).
Background: Cardio-kidney-metabolic (CKM) disease represents a significant public health challenge. While proteomics-based risk scores (ProtRS) enhance cardiovascular risk prediction, their utility in improving risk prediction for a composite CKM outcome beyond traditional risk factors remains unknown.
Methods: We analyzed 23 815 UK Biobank participants without baseline CKM disease, defined by -Tenth Revision codes as cardiovascular disease (coronary artery disease, heart failure, stroke, peripheral arterial disease, atrial fibrillation/flutter), kidney disease (chronic kidney disease or end-stage renal disease), or metabolic disease (type 2 diabetes or obesity).
Stroke
September 2025
Department of Neurology, Yale School of Medicine, New Haven, CT (L.H.S.).
Preclinical stroke research faces a critical translational gap, with animal studies failing to reliably predict clinical efficacy. To address this, the field is moving toward rigorous, multicenter preclinical randomized controlled trials (mpRCTs) that mimic phase 3 clinical trials in several key components. This collective statement, derived from experts involved in mpRCTs, outlines considerations for designing and executing such trials.
View Article and Find Full Text PDF